SPX3,744.52-38.76 -1.02%
DIA299.23-3.56 -1.18%
IXIC11,073.31-75.33 -0.68%

Aytu BioPharma Announces Addition Of Fourth Patent License For AR101/Enzastaurin

ENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a

Benzinga · 09/14/2022 08:09

ENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the addition of a fourth patent to the intellectual property suite surrounding AR101/Enzastaurin. This fourth patent, also licensed from Johns Hopkins University, is titled "Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome," expands the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome (VEDS) and is highly confirmatory of the therapeutic approach for AR101/Enzastaurin. The patent has an expiry date of September 2041, assuming no patent term extensions.